References
- Soucie JM, Evatt B, Jackson D. Occurrence of hemophilia in the United States. The Hemophilia Surveillance System Project Investigators. Am J Hematol 1998;59:288-94
- Arun B, Kessler C. Inherited bleeding disorders: haemostasis and thrombosis. 4th ed. Philadelphia, PA: Lippincott Williams and Wilkens, 2001
- Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357:535-44
- Royal S, Schramm W, Berntorp E, et al. Quality-of-life differences between prophylactic and on-demand factor replacement therapy in European haemophilia patients. Haemophilia 2002;8:44-50
- Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011;9:700-10
- National Hemophilia Foundation. MASAC [Medical and Scientific Advisory Council] Recommendation 179. MASAC Recommendation Concerning Prophylaxis (Regular Administration of Clotting Factor Concentrate to Prevent Bleeding). http://www.hemophilia.org/NHFWeb/MainPgs/MainNHF.aspx?menuid=57&contentid=1007. Accessed April 1, 2013
- Globe DR, Curtis RG, Koerper MA, et al. Utilization of care in haemophilia: a resource-based method for cost analysis from the Haemophilia Utilization Group Study (HUGS). Haemophilia 2004;10(1 Suppl):63-70
- Carlsson KS, Hojgard S, Lindgren A, et al. Costs of on-demand and prophylactic treatment for severe haemophilia in Norway and Sweden. Haemophilia 2004;10:515-26
- Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011;72:553-62
- Gringeri A, Mantovani LG, Scalone L, et al. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group. Blood 2003;102:2358-63
- Auerswald G, von Depka Prondzinski M, Ehlken B, et al. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany. Haemophilia 2004;10:499-508
- Kodra Y, Cavazza M, Schieppati A, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood transfusion = Trasfusione del sangue 2014;12(Suppl 3):s567-75
- Guh S, Grosse SD, McAlister S, et al. Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia 2012;18:268-75
- Tencer T, Friedman HS, Li-McLeod J, et al. Medical costs and resource utilization for hemophilia patients with and without HIV or HCV infection. J Manag Care Pharm 2007;13:790-8
- Guh S, Grosse SD, McAlister S, et al. Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia 2012;18:276-83
- Valentino LA, Pipe SW, Tarantino MD, et al. Healthcare resource utilization among haemophilia A patients in the United States. Haemophilia 2012;18:332-8
- Zhou ZY, Wu J, Baker J, et al. Haemophilia utilization group study - Part Va (HUGS Va): design, methods and baseline data. Haemophilia 2011;17:729-36
- Baker JR, Crudder SO, Riske B, et al. A model for a regional system of care to promote the health and well-being of people with rare chronic genetic disorders. Am J Public Health 2005;95:1910-16
- Soucie JM, Nuss R, Evatt B, et al. Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators. Blood 2000;96:437-42
- Soucie JM, Symons JT, Evatt B, et al. Home-based factor infusion therapy and hospitalization for bleeding complications among males with haemophilia. Haemophilia 2001;7:198-206
- Drake JH, Soucie JM, Cutter SC, et al. High school completion rates among men with hemophilia. Am J Prev Med 2010;38(4 Suppl):S489-94
- HCUPnet: a tool for identifying, tracking, and analyzing national hospital statistics. http://hcupnet.ahrq.gov/HCUPnet.jsp. Accessed May 2, 2012
- Centers for Medicare & Medicaid Services. MEDPAR. http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareFeeforSvcPartsAB/MEDPAR.html. Accessed April 28, 2012
- Machlin S, Chowdhury S. Expenses and characteristics of physician visits in different ambulatory care settings, 2008. http://meps.ahrq.gov/mepsweb/data_files/publications/st318/stat318.pdf. Accessed April 24, 2012
- Centers for Medicare & Medicaid Services. Medicare Physician Fee Schedule. http://www.cms.gov/apps/physician-fee-schedule/. Accessed April 22, 2012
- Centers for Medicare & Medicaid Services. Medicare Part B Drug Average Sales Price. https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McrPartBDrugAvgSalesPrice/index.html. Accessed April 26, 2012
- Ready price. 2012. http://www.micromedexsolutions.com/home/dispatch. Accessed January 27, 2012
- Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem Fund Q Health Soc 1982;60:429-62
- U.S. Bureau of Labor Statistics. Employer costs per hour worked for employee compensation. 2011. www.bls.gov/. Accessed February 24, 2012
- Agency for Healthcare Research and Quality. Total health services-mean and median expenses per person with expense and distribution of expenses by source of payment: United States, 2010. Medical Expenditure Panel Survey Household Component Data. http://meps.ahrq.gov/survey_comp/household.jsp. Accessed April 28, 2013
- Centers For Disease Control and Prevention Blood Disorders. Information for hemophilia treatment centers. http://www.cdc.gov/ncbddd/blooddisorders/udc/udc-hemophilia.html. Accessed April 10, 2013
- Soucie JM, Cianfrini C, Janco RL et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004;103:2467-73
- Baker JR, Riske B, Drake JH, et al. US Hemophilia Treatment Center population trends 1990-2010: patient diagnoses, demographics, health services utilization. Haemophilia 2013;19:21-6